In summary, these data collectively indicate that GF9 generates a strong anti‐arthritic effect in CIA, thereby providing the first experimental in vivo evidence of previously predicted immunomodulatory activity of this peptide in TREM‐1‐mediated autoimmune diseases including RA 18. Here, TREM1 is linked to rheumatoid arthritis.